X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES JUBILANT LIFE SCIENCES ALKEM LABORATORIES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x - 29.2 - View Chart
P/BV x 7.3 6.0 122.2% View Chart
Dividend Yield % 0.6 0.3 194.9%  

Financials

 ALKEM LABORATORIES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
ALKEM LABORATORIES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,589187 850.6%   
Low Rs1,23265 1,892.5%   
Sales per share (Unadj.) Rs417.5364.3 114.6%  
Earnings per share (Unadj.) Rs56.36.8 822.3%  
Cash flow per share (Unadj.) Rs64.724.5 264.1%  
Dividends per share (Unadj.) Rs12.703.00 423.3%  
Dividend yield (eoy) %0.92.4 37.8%  
Book value per share (Unadj.) Rs292.9164.9 177.6%  
Shares outstanding (eoy) m119.57159.28 75.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 977.4%   
Avg P/E ratio x25.118.4 136.2%  
P/CF ratio (eoy) x21.85.1 424.0%  
Price / Book Value ratio x4.80.8 630.4%  
Dividend payout %22.643.8 51.5%   
Avg Mkt Cap Rs m168,65320,061 840.7%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m9,17111,052 83.0%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m49,91558,034 86.0%  
Other income Rs m1,645191 863.1%   
Total revenues Rs m51,56158,224 88.6%   
Gross profit Rs m8,4825,786 146.6%  
Depreciation Rs m1,0062,812 35.8%   
Interest Rs m6713,237 20.7%   
Profit before tax Rs m8,451-72 -11,721.2%   
Minority Interest Rs m-114-286 39.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m1,606696 230.6%   
Profit after tax Rs m6,7311,090 617.3%  
Gross profit margin %17.010.0 170.4%  
Effective tax rate %19.0-965.9 -2.0%   
Net profit margin %13.51.9 717.7%  
BALANCE SHEET DATA
Current assets Rs m27,06229,280 92.4%   
Current liabilities Rs m15,32438,912 39.4%   
Net working cap to sales %23.5-16.6 -141.7%  
Current ratio x1.80.8 234.7%  
Inventory Days Days6784 78.8%  
Debtors Days Days4151 81.4%  
Net fixed assets Rs m12,61055,712 22.6%   
Share capital Rs m239155 154.8%   
"Free" reserves Rs m34,49020,968 164.5%   
Net worth Rs m35,02726,265 133.4%   
Long term debt Rs m1,21217,169 7.1%   
Total assets Rs m54,38788,606 61.4%  
Interest coverage x13.61.0 1,391.2%   
Debt to equity ratio x00.7 5.3%  
Sales to assets ratio x0.90.7 140.1%   
Return on assets %13.64.9 278.6%  
Return on equity %19.24.2 462.9%  
Return on capital %24.911.6 214.9%  
Exports to sales %12.937.8 34.2%   
Imports to sales %3.116.5 18.7%   
Exports (fob) Rs m6,46121,933 29.5%   
Imports (cif) Rs m1,5409,567 16.1%   
Fx inflow Rs m6,56322,004 29.8%   
Fx outflow Rs m3,01211,749 25.6%   
Net fx Rs m3,55210,255 34.6%   
CASH FLOW
From Operations Rs m7,2598,026 90.4%  
From Investments Rs m1,864-1,744 -106.9%  
From Financial Activity Rs m-9,273-4,447 208.5%  
Net Cashflow Rs m-1501,834 -8.2%  

Share Holding

Indian Promoters % 66.9 45.6 146.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 33.1 8.7 380.5%  
FIIs % 0.0 21.2 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 21.1 -  
Shareholders   68,381 23,815 287.1%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   DISHMAN PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 21, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS